Company acquired ordinary shares from the subsidiary company in Quarter 2/2018. Finance cost Q2/2019, finance cost was increased from the prior year same period at Baht 2.4 million, which was increased
resolved to propose that the 2018 Annual Ordinary General Meeting of Shareholders to be held on April 20, 2018 consider granting approval for the Company to execute the Agreement for Engagement of CH
.(100) 68.9 (149.2
business), i.e., disposing ordinary shares of NU of 30,599,999 shares, equivalent to 90 percent of the total NU shares to Chirasak Chiyachantana Ph.D. Asso.Prof. at an approximate price of Baht 8.3824 per
) 25.6 95.5 (149.2) (127.4) (21.8) Net profit from ordinary activities attributable to the parent 305.6 338.1 341.3 393.3 52.0 15.2% 1,358.4 1,378.3 19.9 1.5% * Extraordinary items from non-operating
. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public
the same period of 2017. Excluding TBSP of 16.9% GP, Company’s %GP represented at 24.1%, slightly growth primary by higher Gross Profit of Digital Print & Mail business. %Gross Profit Margin Mil THB 330
to 130.80 million Baht, while cost of distributions and administrative expenses and financial costs were 34.22 million Baht in total. Net income for the period of the company was 9.71 million Baht. The